New weight loss drug GZR18 enters final testing phase
NCT ID NCT06728124
First seen Jan 04, 2026 · Last updated Jun 22, 2026 · Updated 25 times
Summary
This Phase 3 study tests an investigational drug called GZR18 for weight loss in 630 adults who are obese or overweight with related health issues. Participants receive either GZR18 or a placebo injection, and researchers measure weight change over time. The trial is double-blind and placebo-controlled to ensure reliable results.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing
Beijing, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GZR18 injection
What this could lead to
If successful, this could provide a new medication option for significant weight loss in people with obesity or overweight.
What could go wrong
This is a Phase 3 trial, but results are not yet available. The drug may cause side effects or not prove more effective than placebo.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.